Is India Ready to Become an Innovation-Led Pharma Giant in the Next 5 Years?
Click to start listening
Synopsis
India is on the brink of a significant transformation in its pharmaceutical sector, shifting from being the 'pharmacy of the world' to an innovation-driven leader. The CDSCO's reforms and focus on advanced research and development are set to redefine India's role in global healthcare.
Key Takeaways
- India's pharmaceutical sector is transforming towards innovation.
- CDSCO reforms are pivotal for R&D growth.
- Emphasis on biosimilars and complex generics is increasing.
- Hospital finance scheme of Rs 1,00,000 crore supports innovation.
- Indian manufacturers are gearing up for high-value markets.
New Delhi, Nov 26 (NationPress) India is strategically poised to transform from being the pharmacy of the world into an innovation-driven pharmaceutical powerhouse within the next five years, according to Dr. R Chandrashekar, Joint Drugs Controller at the Central Drugs Standard Control Organization (CDSCO).
He made these remarks during the three-day 18th CPHI & PMEC India event taking place in Greater Noida from November 25 to November 27.
“The reforms introduced by the government and CDSCO, including streamlined approval processes, fewer regulatory hurdles, the decriminalization of minor offences, and a recommendation for R&D projects amounting to Rs 5,000 crore, are pivotal. The newly unveiled hospital finance scheme of Rs 1,00,000 crore further enhances India’s R&D environment,” Chandrashekar stated while addressing the press.
He further highlighted that India’s pharmaceutical industry is swiftly transitioning from a generics-centric model to an innovation-focused ecosystem, with a growing concentration on biosimilars, peptides, complex generics, and next-generation biologics.
Namit Joshi, Chairman of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), emphasized the necessity for India to move past its conventional generics approach and embrace cross-domain insights along with a more innovation-oriented strategy to enhance India’s position in shaping the future of global healthcare.
“The future is grounded in value-driven innovation, improving capabilities in peptides, complex generics, biosimilars, biologics, targeted drug delivery systems, and cell and gene therapies. Breakthrough classes like GLP-1 inhibitors are transforming global health outcomes, and Indian manufacturers are gearing up to enter these high-value markets as patents expire,” Joshi noted.
Anil Matai, Director General of the Organization of Pharmaceutical Producers of India (OPPI), remarked that while India has solidified its reputation as the ‘Pharmacy to the World,’ it is now evolving into a bona fide pharmaceutical powerhouse.
“This transformation is facilitated by supportive regulations, enhanced processes, and an increased focus on innovation, robust intellectual property protection, and the eradication of patent violations. These reforms mirror the government’s broader vision to ‘discover in India, innovate in India, and innovate for the world,’ and the initial steps towards that future are already observable,” Matai concluded.
Point of View
India is on the verge of a pivotal evolution in the pharmaceutical sector. The emphasis on innovation and research underlines a strategic shift that can enhance India's global standing. The reforms led by CDSCO and government initiatives are commendable steps towards achieving this vision. It's imperative for India to embrace this change to not only benefit its economy but also contribute significantly to global health.
NationPress
26/11/2025
Frequently Asked Questions
What is the role of CDSCO in India's pharmaceutical sector?
The Central Drugs Standard Control Organization (CDSCO) plays a crucial role in regulating pharmaceuticals in India, ensuring safety, efficacy, and quality of drugs, and facilitating reforms to enhance innovation.
What are the key areas of focus for India's pharmaceutical innovation?
India’s pharmaceutical innovation is focusing on biosimilars, peptides, complex generics, and next-generation biologics, aiming to transition from a generics-driven model.
How much is the new hospital finance scheme introduced in India?
The new hospital finance scheme launched in India amounts to Rs 1,00,000 crore, aimed at bolstering research and development in the pharmaceutical sector.
Why is there a need to shift from generics to innovation in India?
Shifting from generics to innovation is essential for India to compete globally, improve healthcare outcomes, and tap into high-value market segments as patents expire.
What are GLP-1 inhibitors and their significance?
GLP-1 inhibitors are breakthrough drugs that significantly improve health outcomes for diabetes and obesity. Indian manufacturers are preparing to enter this lucrative market as patents expire.
